Results 71 to 80 of about 28,618 (205)

Inosine‐Triphosphate‐Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients do not respond to it. Low inosine triphosphate pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated the role and underlying mechanisms of ITPA in vitro. Methods ITPA enzymatic activity
Sofia Sindici Forgiarini, Marianna Lucafò, Debora Curci, Davide Selvestrel, Valentina Moressa, Sofia Pagarin, Barbara Bellich, Martina Franzin, Alberto Tommasini, Mara L. Becker, Laura B. Ramsey, Susan D. Thompson, Carl D. Langefeld, Federica Corba, Edoardo Marrani, Gabriele Simonini, Gabriele Stocco, Giuliana Decorti, Andrea Taddio, Serena Pastore   +19 more
wiley   +1 more source

Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy

Cancer Biology & Medicine
This review examined the critical role of adenosine signaling in modulating the behavior of tumor-associated macrophages (TAMs), a key determinant of the tumor microenvironment (TME).
Lei Yang, Yi Zhang, Li Yang
doaj   +1 more source

Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

Biomolecules, 2023
In rheumatoid arthritis (RA) synovium, ATP, and ADP are released, sparking inflammation. Ectoenzymes CD39 and CD73 metabolize these purine nucleotides, generating anti-inflammatory adenosine. Therefore, dysregulated CD39 and CD73 expression may impact RA
María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hector Corominas, Silvia Vidal   +10 more
doaj   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Autoreactivity vs autoimmunity: characteristics of autoantigen‐specific CD4 T‐cells in rheumatoid arthritis and health.

Arthritis &Rheumatology, Accepted Article.
Background CD4 T cells specific for citrullinated (cit)‐peptides are key players in RA immunopathogenesis. Characterising these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next generation of RA treatments.
James A. Stanway, Daniel Peters, Helen Waller, Jeremy Lakey, Henrique De Paula Lemos, Kristian Williams, Abbie Degnan, Julie Diboll, Abdul Mannan Baru, David Tough, Arthur G. Pratt, Catharien M.U. Hilkens, Amy E. Anderson, John D. Isaacs   +13 more
wiley   +1 more source

The NOTCH1/CD39 axis: a Treg trip-switch for GvHD [PDF]

Leukemia, 2016
Regulatory T cells (Tregs) suppress alloimmune reaction such as graft versus host disease (GvHD)1 and promote tolerance induction to allogeneic organ transplants.2 In high-risk acute leukaemia patients undergoing full-haplotype mismatched transplantation we demonstrated that adoptive immunotherapy with Tregs conventional T cells (Tcons) almost ...
DEL PAPA, BEATRICE, PIERINI, ANTONIO, SPORTOLETTI, PAOLO, BALDONI, STEFANO, CECCHINI, DEBORA, ROSATI, Emanuela, DORILLO, ERICA, AURELI, PATRIZIA, ZEI, TIZIANA, Iacucci Ostini, R., RUGGERI, Loredana, Carotti, A., VELARDI, Andrea, Negrin, R., MARTELLI, Massimo Fabrizio, FALZETTI, Franca, DI IANNI, Mauro   +16 more
openaire   +4 more sources

Endogenous antisense RNA curbs CD39 expression in Crohn’s disease

Nature Communications, 2020
CD39 is an ectonucleotidase associated with immunoregulatory function. Here authors show regulation of CD39 expression by an endogenous antisense RNA moiety transcribed from the 3‘ end of CD39/ENTPD1 which when itself is silenced results in amelioration ...
Rasika P. Harshe, Anyan Xie, Marta Vuerich, Luiza Abrahão Frank, Barbora Gromova, Haohai Zhang, Rene’ J. Robles, Samiran Mukherjee, Eva Csizmadia, Efi Kokkotou, Adam S. Cheifetz, Alan C. Moss, Satya K. Kota, Simon C. Robson, Maria Serena Longhi   +14 more
doaj   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source